BNTX Shares Rise 10%, EU Begins Review of BioNTech-Pfizer Vaccine
The start of the review process of the BioNTech-Pfizer vaccine has triggered investors to bet more on BNTX stock.The European Union’s European Medicines Agency (EMA) has commenced the review of BNT162b2, the BioNTech-Pfizer COVID-19 vaccine candidate being developed by the duo of BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE:
Read More